Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × amino-acid, glucose, and electrolyte solution × Clear all
NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡